Literature DB >> 26824711

Long-term Therapeutic Outcomes of Radiofrequency Ablation for Subcapsular versus Nonsubcapsular Hepatocellular Carcinoma: A Propensity Score Matched Study.

Tae Wook Kang1, Hyo Keun Lim1, Min Woo Lee1, Young-Sun Kim1, Hyunchul Rhim1, Won Jae Lee1, Yong Han Paik1, Min Ji Kim1, Joong Hyun Ahn1.   

Abstract

Purpose To compare the long-term therapeutic outcomes of radiofrequency (RF) ablation for hepatocellular carcinoma (HCC) in subcapsular versus nonsubcapsular locations by using propensity score matching. Materials and Methods RF ablation for subcapsular HCC is controversial because of a high risk of incomplete ablation or major complications. This retrospective study was approved by the institutional review board, and the requirement for informed consent was waived. Between April 2006 and December 2011, 508 consecutive patients (396 men, 112 women; age range, 30-80 years) with a single HCC (Barcelona Clinic Liver Cancer stage 0 or A) underwent ultrasonography-guided percutaneous RF ablation as a first-line treatment. The patients were divided into two groups according to tumor location: subcapsular (n = 227) and nonsubcapsular (n = 281). Subcapsular HCC was defined as an index tumor located within 0.1 cm of the liver capsule. The association of subcapsular location and therapeutic outcomes of RF ablation was evaluated, including (a) local tumor progression (LTP) by using a competing risk regression model and (b) overall survival (OS) by using a Cox proportional hazards model according to propensity score matched data. The major complication rates from both overall data and matched data were assessed. Results Matching yielded 163 matched pairs of patients. In the two matched groups, cumulative LTP rates were 18.8% and 20.9% at 3 and 5 years, respectively, in the subcapsular group and 13.2% and 16.0% in the nonsubcapsular group. Corresponding OS rates were 90.7% for 3 years and 83.2% for 5 years in the subcapsular group and 91.4% and 79.1%, respectively, in the nonsubcapsular group. Hazard ratios (HRs) for LTP (HR = 1.37, P = .244) and OS (HR = 0.86, P = .604) were not significantly different between the two matched groups. Additionally, differences in major complication rates were not significant between groups for the two sets of data (P > .05). Conclusion The differences in LTP, OS, and major complication rates of RF ablation for HCC were not significant between subcapsular and nonsubcapsular groups. (©) RSNA, 2016.

Entities:  

Mesh:

Year:  2016        PMID: 26824711     DOI: 10.1148/radiol.2016151243

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  27 in total

1.  Ablative safety margin depicted by fusion imaging with post-treatment contrast-enhanced ultrasound and pre-treatment CECT/CEMRI after radiofrequency ablation for liver cancers.

Authors:  Xiao-Wan Bo; Hui-Xiong Xu; Le-Hang Guo; Li-Ping Sun; Xiao-Long Li; Chong-Ke Zhao; Ya-Ping He; Bo-Ji Liu; Dan-Dan Li; Kun Zhang; Dan Wang
Journal:  Br J Radiol       Date:  2017-07-27       Impact factor: 3.039

2.  Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.

Authors:  Saleh A Alqahtani; Faisal M Sanai; Ashwaq Alolayan; Faisal Abaalkhail; Hamad Alsuhaibani; Mazen Hassanain; Waleed Alhazzani; Abdullah Alsuhaibani; Abdullah Algarni; Alejandro Forner; Richard S Finn; Waleed K Al-Hamoudi
Journal:  Saudi J Gastroenterol       Date:  2020-10       Impact factor: 2.485

3.  Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.

Authors:  Zhenwei Peng; Mengchao Wei; Shuling Chen; Manxia Lin; Chunlin Jiang; Jie Mei; Bin Li; Yu Wang; Jiaping Li; Xiaoyan Xie; Ming Kuang
Journal:  Eur Radiol       Date:  2018-03-13       Impact factor: 5.315

4.  Reducing Pain by Artificial Ascites Infusion During Radiofrequency Ablation for Subcapsular Hepatocellular Carcinoma.

Authors:  Sae-Jin Park; Dong Ho Lee; Joon Koo Han
Journal:  Cardiovasc Intervent Radiol       Date:  2021-01-03       Impact factor: 2.740

5.  Percutaneous cryoablation for perivascular hepatocellular carcinoma: Therapeutic efficacy and vascular complications.

Authors:  Ran Kim; Tae Wook Kang; Dong Ik Cha; Kyoung Doo Song; Min Woo Lee; Hyunchul Rhim; Hyo Keun Lim; Dong Hyun Sinn
Journal:  Eur Radiol       Date:  2018-07-24       Impact factor: 5.315

6.  Percutaneous thermal ablation of subcapsular hepatocellular carcinomas: influence of tumor-surface contact and protrusion on therapeutic efficacy and safety.

Authors:  Akeanong Worakitsitisatorn; David S Lu; Min Woo Lee; Nazanin H Asvadi; Amin Moshksar; Alexander D Yuen; Justin McWilliams; Steven S Raman
Journal:  Eur Radiol       Date:  2019-12-10       Impact factor: 5.315

7.  Percutaneous US-guided MWA of small liver HCC: predictors of outcome and risk factors for complications from a single center experience.

Authors:  Pierpaolo Biondetti; Enrico Maria Fumarola; Anna Maria Ierardi; Andrea Coppola; Giovanna Gorga; Luca Maggi; Elena Valconi; Salvatore Alessio Angileri; Gianpaolo Carrafiello
Journal:  Med Oncol       Date:  2020-04-02       Impact factor: 3.064

Review 8.  Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.

Authors:  Josep M Llovet; Thierry De Baere; Laura Kulik; Philipp K Haber; Tim F Greten; Tim Meyer; Riccardo Lencioni
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-01-28       Impact factor: 46.802

9.  Laparoscopic Liver Resection versus Percutaneous Radiofrequency Ablation for Small Single Nodular Hepatocellular Carcinoma: Comparison of Treatment Outcomes.

Authors:  Dong Ho Lee; Jing Woong Kim; Jeong Min Lee; Jong Man Kim; Min Woo Lee; Hyunchul Rhim; Young Hoe Hur; Kyung-Suk Suh
Journal:  Liver Cancer       Date:  2021-01-14       Impact factor: 11.740

10.  Switching Monopolar No-Touch Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma: A Randomized Clinical Trial.

Authors:  Sae-Jin Park; Eun Ju Cho; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon; Hyo-Jin Kang; Jeong Hee Yoon; Dong Ho Lee; Se Hyung Kim; Jae Young Lee; Jeong Min Lee
Journal:  Liver Cancer       Date:  2020-12-08       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.